Suspected acute coronary syndrome in the emergency room: Limited added value of heart type fatty acid binding protein point of care or ELISA tests: The FAME-ER (Fatty Acid binding protein in Myocardial infarction Evaluation in the Emergency Room) study

Abstract

Background:

Timely recognition of acute coronary syndrome remains a challenge as many biomarkers, including troponin, remain negative in the first hours following the onset of chest pain. We assessed the diagnostic accuracy of heart-type fatty acid binding protein (H-FABP), a cardiac biomarker with potential value immediately post symptom onset.

Methods and results:

Prospective monocentre diagnostic accuracy study of H-FABP bedside point of care (CardioDetect®) and ELISA tests in acute coronary syndrome suspected patients presenting within 24 hours of symptom onset to the emergency department, in addition to clinical findings, electrocardiography and the currently recommended biomarker high sensitivity troponin-T (hs-cTnT). The final diagnosis of acute coronary syndrome was adjudicated by two independent cardiologists, blinded to H-FABP results. Acute coronary syndrome was diagnosed in 149 (32.9%) of 453 unselected patients with suspected acute coronary syndrome (56% men, mean age 62.6 years). Negative predictive values were similar for H-FABP point of care and ELISA tests (79% vs. 78% respectively), but inferior to initial hs-cTnT (negative predictive value 86%). The addition of H-FABP point of care results to hs-cTnT increased the negative predictive value to 89%. In a multivariable logistic regression model, H-FABP point of care and ELISA tests yielded relevant diagnostic information in addition to clinical findings and ECG (likelihood ratio test p<0.001) and increased area under the receiver operating characteristics curve (AUC; 0.82 vs. 0.84 and 0.84). This added value attenuated, however, after inclusion of hs-cTnT in the diagnostic model (AUC 0.88).

Conclusions:

In patients suspected of acute coronary syndrome presenting to the emergency department, H-FABP testing improves diagnostic accuracy in addition to clinical findings and electrocardiography. H-FABP, however, has no additional diagnostic value when hs-cTnT measurements are also available.

Keywords

Acute coronary syndrome (ACS)biomarker heart-type fatty acid binding protein (H-FABP)point-of care test high sensitivity troponin

Get full access to this article

View all access options for this article.

References

Thygesen

Alpert

Jaffe

. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551–2567.

Keller

Zeller

Peetz

. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361: 868–877.

Hamm

Bassand

J-P

Agewall

. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevatio. Eur Heart J 2011; 32: 2999–3054.

Bruins Slot

MHE

Reitsma

Rutten

. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction: A systematic review and meta-analysis. Heart 2010; 96: 1957–1963.

Carroll

Al Khalaf

Stevens

. Heart-type fatty acid binding protein as an early marker for myocardial infarction: Systematic review and meta-analysis. Emerg Med J 2013; 30: 280–286.

Lippi

Mattiuzzi

Cervellin

. Critical review and meta-analysis on the combination of heart-type fatty acid binding protein (H-FABP) and troponin for early diagnosis of acute myocardial infarction. Clin Biochem 2013; 46: 26–30.

McCann

Glover

Menown

. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J 2008; 29: 2843–2850.

McMahon

Lamont

J V

Curtin

. Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med 2012; 30: 267–274.

Pelsers

MMAL

Hermens

Glatz

JFC

. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005; 352: 15–35.

10.

Charpentier

Maupas-Schwalm

Cournot

. Diagnostic accuracy of quantitative heart-fatty acid binding protein assays compared with Cardiodetect(®) in the early detection of acute coronary syndrome. Arch Cardiovasc Dis 2011; 104: 524–529.

11.

Glatz

JFC

Renneberg

. Added value of H-FABP as plasma biomarker for the early evaluation of suspected acute coronary syndrome. Clin Lipidol 2014; 9: 205–220.

12.

Reiter

Twerenbold

Reichlin

. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction. Heart 2013; 99: 708–714.

13.

Eggers

Venge

Lindahl

. High-sensitive cardiac troponin T outperforms novel diagnostic biomarkers in patients with acute chest pain. Clin Chim Acta 2012; 413: 1135–1140.

14.

Collinson

Gaze

Goodacre

. Comparison of contemporary troponin assays with the novel biomarkers, heart fatty acid binding protein and copeptin, for the early confirmation or exclusion of myocardial infarction in patients presenting to the emergency department with chest pain. Heart 2014; 100: 140–145.

15.

Aldous

Pemberton

Troughton

. Heart fatty acid binding protein and myoglobin do not improve early rule out of acute myocardial infarction when highly sensitive troponin assays are used. Resuscitation 2012; 83: e27–e28; author reply e29–e30.

16.

Ruff

Bonaca

Kosowsky

. Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. J Thromb Thrombolysis 2013; 36: 361–367.

17.

Bossuyt

Reitsma

Bruns

. Towards comp-lete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Fam Pract 2004; 21: 4–10.

18.

Donders a

van der Heijden

GJMG

Stijnen

. Review: A gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087–1091.

19.

Pencina

D’Agostino

Steyerberg

. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11–21.

20.

Harrell

Lee

Mark

. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361–387.

21.

Raskovalova

Twerenbold

Collinson

. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: A systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care 2014; 3: 18–27.

22.

Searle

Slagman

Stockburger

. Use of copeptin in emergency patients with cardiac chief complaints. Eur Heart J Acute Cardiovasc Care. Epub ahead of print 15 October 2014. DOI: 10.177/2048872614554197.

23.

Bandstein

Ljung

Johansson

. Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. J Am Coll Cardiol 2014; 63: 2569–2578.

24.

Body

Carley

McDowell

. The Manchester Acute Coronary Syndromes (MACS) decision rule for suspected cardiac chest pain: Derivation and external validation. Heart 2014; 100: 1462–1468.

25.

Möckel

Searle

Hamm

. Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): A randomized, controlled clinical process study. Eur Heart J 2014; 369–376.

26.

Bohyn

Dubie

Lebrun

. Expeditious exclusion of acute coronary syndrome diagnosis by combined measurements of copeptin, high-sensitivity troponin, and GRACE score. Am J Emerg Med 2014; 32: 293–296.

27.

Forberg

Henriksen

Edenbrandt

. Direct hospital costs of chest pain patients attending the emergency department: A retrospective study. BMC Emerg Med 2006; 6: 6.